PRNews

Frost & Sullivan Applauds STANLEY Healthcare’s Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry

STANLEY Healthcare’s user-friendly, unobtrusive innovations address challenges in the market, making senior living communities tech savvy and future ready for implementing efficient senior care

SANTA CLARA, California, Sept. 7, 2017 /PRNewswire/ — Based on its recent analysis of the market for technology solutions for senior living communities, Frost & Sullivan recognizes STANLEY Healthcare with the 2017 Global Company of the Year Award. STANLEY Healthcare, a business unit of the Fortune 500 Company Stanley Black & Decker, is a leading solutions vendor for hospitals, health systems, and the senior living space. STANLEY Healthcare aims to expand its suite of solutions for the senior living market and deliver greater value to its clients in supporting their provision of senior care in an increasingly challenging environment.


STANLEY Healthcare receives the 2017 Global Senior Living Community Vendor Company of the Year Award

STANLEY Healthcare’s solutions serve several safety and security needs of senior living communities. These solutions include emergency call, wander management, staff security, facility security, and temperature monitoring. STANLEY Healthcare is the leader in fall management solutions, with over a million fall monitors installed over the past decade.

Going beyond its existing solutions and realizing the industry’s upcoming needs, STANLEY Healthcare is working to realize the ‘Smart Resident Room’. Integrating sensors in an Internet of Things fashion, the Smart Room concept will enable senior living communities to monitor residents unobtrusively while they carry on with their daily activities.

“Realizing the nature of technology and acknowledging the fast-changing pace of advancements, STANLEY Healthcare routinely partners with other technology companies whose solutions can integrate with its own to provide enhanced value for its customers,” said Industry Analyst Siddharth Shah at Frost & Sullivan. “It also partners with some of the WLAN and infrastructure providers to ensure its products and software work seamlessly with customers’ wireless infrastructure.”

An example of innovative technology founded on market needs is a wander management system using Bluetooth Low Energy (BLE) for wireless communication. “To lower the barriers to entry for wireless solutions, STANLEY Healthcare is moving towards using BLE solutions. Designing solutions that are appealing enough to attract residents is an approach that helps STANLEY Healthcare differentiate its solutions from others available in the senior living space,” said Shah.

Another key differentiator that distinguishes STANLEY Healthcare from the competition is its approach to customer care, including:

  • Product support services spanning the entire lifecycle of the solution.
  • The By Your Side™ customer support portal, which helps clients obtain answers to their queries, provides access to product documentation, and extends support for solving technical challenges.
  • 24/7 phone support, remote diagnostics, and on-site repair services.

Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to execute successfully a competitive strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About STANLEY Healthcare

STANLEY Healthcare provides over 5,000 acute care hospitals and 12,000 long-term care organizations with enterprise solutions that create a safe, secure and efficient healthcare experience across life’s stages. The STANLEY Healthcare solution set enables customers to achieve organizational excellence and superior care in critical areas: Patient/Resident Safety, Security & Protection, Environmental Monitoring, Clinical Operations & Workflow and Supply Chain & Asset Management. These solutions are complemented by STANLEY Healthcare’s By Your Side™ Lifetime Customer Care commitment to ensure that every customer achieves success and realizes the full value of their investment, through consulting, training, implementation and integration services. STANLEY Healthcare is proud to be part of Stanley Black & Decker, Inc. For more information, visit stanleyhealthcare.com. Follow STANLEY Healthcare on Facebook, Twitter, LinkedIn and YouTube.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Claudia Toscano
P: 210.477.8417
F: 210.348.1003
E: claudia.toscano@frost.com

PRNews

15 million Connected Disposable Medical Sensors to Ship by 2023

Vendors are investing to further the potential of a range of single-use, wireless healthcare sensors.

OYSTER BAY, N.Y., Sept. 7, 2017 /PRNewswire/ — The adoption of an emerging generation of disposable, connected sensors will be driven by the ongoing development of remote patient monitoring applications, according to the latest healthcare report from ABI Research. Combined with use in hospitals and clinics, shipments of single-use sensors capable of transmitting patient data wirelessly, will exceed 3.5 million sensors annually by 2022, growing at a CAGR of 30% from 2016 shipments.

“Disposables are already a feature of healthcare provision around the globe and medical sensors will have to fit into that world. Efforts already underway promise considerable progress over the next few years,” says Jonathan Collins, Research Director at ABI Research. “Their potential to extend and simplify the benefits of remote patient monitoring will help drive the adoption of both,” he says.

Disposable sensors, without embedded wireless transmitters are already commonplace in remote patient continuous glucose monitoring applications from Dexcom, Medtronic and others, but their potential reaches far beyond. Disposable connected sensors can support applications including medication tracking, temperature, heart rate and pulse oximetry as well as activity/movement/post-surgery orthopedics monitoring that address a far larger user-base.

A host of companies ranging from established players including Philips Healthcare and Medtronic to well-backed ventures like Qualcomm Life and smaller start-ups like GenTag and Proteus Digital Health are all investing in developing disposable sensors, but are taking varied approaches regarding sensor format and supporting technologies. In addition, a range of wireless protocols are under consideration for adoption in disposable smart health sensors including Bluetooth, NFC and Proprietary offerings.

“What these and many other companies share is an understanding that healthcare workflows and reimbursement payments are already steeped in the broad use of disposable devices. Between now and 2022 will be a key time for these vendors and others to address technical and ecosystem complexity around disposable sensor connectivity. It will also be the primary time for vendors to gain a foothold in the emerging market,” says Collins.

These findings are from ABI Research’s Disposable Medical Sensors report. This report is part of the company’s Smart Health research service, which includes research, data, and analyst insights. 

About ABI Research

ABI Research stands at the forefront of technology market intelligence, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

PRNews

Vatech Introduces the PaX-i Insight – the Latest Evolution in 2D Imaging

FORT LEE, N.J., Sept. 1, 2017 /PRNewswire/ —  Vatech officially launches the PaX-i Insight, the next generation of panoramic technology. PaX-i Insight aims to deliver an astonishing feature of adding depths to a panoramic image.


Depth added panoramic image

The all new PaX-i Insight features the ‘Insight Pan’, which is the 4th generation of panoramic radiography presented by Vatech for the first time in the market. While the conventional panoramic systems may miss important details which land outside of a single focal trough, the PaX-i Insight is capable of taking multi-layered images and providing in-depth look across a single focal trough.

Having the option to choose from a variety of images, the Insight Pan offers clinicians to explore 41 images (each sliced in 1 mm) when exploring their region of interest. This feature not only provides an accurate diagnosis for periapical diseases, periodontitis and pericoronitis but also allows clinicians to find hidden roots and canals.

In the case studies released by Vatech, visible fractured roots are often ‘missed out’ in conventional panoramic images with a single layer. Utilizing the PaX-i Insight’s ‘multi-slice’ mode, clinicians can discover buccal roots by examining each root and its periodontal ligament separately.

One notable feature of the PaX-i Insight is the 1.9 second acquisition time. Cephalometry radiography is an essential part of an orthodontic treatment and yet, it was not always easy to acquire a superb image quality that clinicians desire due to the motion artifact. Standing still for 12 seconds is difficult especially for children and teenagers. Furthermore, any movement during the image acquisition would leave clinicians with blurred images. Now with PaX-i Insight’s rapid ceph technology, clinicians can obtain accurate images in the shortest time span by minimizing motion artifacts.

Besides the functionality of the PaX-i Insight, the user-friendly EzDent-i software serves as a powerful solution to maximize the capability of the PaX-i Insight. The Easy-to-use interface allows clinicians to be more efficient with treatment planning and patient consultation. An efficient practice leads to a much better standard of care delivered to the patients.

“We are glad to present Vatech’s latest innovation which fascinated many clinicians at the IDS 2017. The new product will not only reduce the number of retakes by accurately exploring anatomical structures of the teeth but also enable faster diagnostic workflow. Since PaX-i Insight offers a unique feature which other products could not produce, we are all eager to see how this new product will transform the way clinicians work on their cases and communicate with their patients,” said Brian Hwang, CEO of Vatech America.

PaX-i Insight will make its first release in the United States. Shortly, the new product will be introduced to other global markets throughout the year; including Germany, Italy and France. For more information, please visit www.vatechamerica.com.

About Vatech America Inc.

Vatech is a leading provider of digital dental radiography products. As the US subsidiary of Vatech Co., Ltd., Vatech America is dedicated solely to innovative digital dental X-ray imaging technologies that aid dentists and ultimately help to improve the health of dental patients. The company is responsible for technological advances in recent years that offer every American dental practice, from small to large, endless possibilities to achieve higher standards.

PR Contact
June Chang
+1-201-210-5028
jchang@vatechamerica.com 
Vatech America


PaX-i Insight

View original content with multimedia:http://www.prnewswire.com/news-releases/vatech-introduces-the-pax-i-insight—the-latest-evolution-in-2d-imaging-300512079.html

Source: Vatech Co., Ltd.

PRNews

European XFEL: World’s Largest X-ray Laser to Launch in Hamburg

HAMBURG, Germany, Sept. 1, 2017 /PRNewswire/ —

From 1 September 2017, the European XFEL – the world‘s biggest X-ray laser – will be in regular operation. The €1.22 billion research facility in the Hamburg Metropolitan Region involves eleven European countries. 

The facility is a project of superlatives: with 27,000 X-ray laser flashes per second and a luminance a billion times higher than that of the best conventional X-ray sources, XFEL will open up entirely new research opportunities and help transcend the current boundaries of scientific research. It will enable international scientists to decipher the molecular composition of viruses and cells, take three-dimensional images of the nanoworld, film chemical reactions and study processes occurring deep inside planets. XFEL will help develop e.g. new medication and new materials.

This Friday, the facility will be launched by Germany’s Research Minister Johanna Wanka, Hamburg’s First Mayor Olaf Scholz, Schleswig-Holstein’s Science Minister Karin Prien, Russia’s Presidential Advisor Andrei Fursenko, French Research Minister Frédérique Vidal and other high-ranking representatives. They will be joined by several external researchers, who are currently preparing for their first experiments in mid-September.

XFEL is a non-profit organisation that closely collaborates with DESY Hamburg and other international institutions. It employs about 300 people. With a cost of €1.22 billion for construction and launch and a 3.4-kilometre tunnel system that extends to the state of Schleswig-Holstein, it is among Europe’s biggest and most ambitious research projects. Eleven countries are involved: Denmark, France, Germany, Hungary, Italy, Poland, Russia, Slovakia, Spain, Sweden, Switzerland; the UK is in the process of joining. For Hamburg as a science and business location, XFEL marks a further step in establishing itself as an international innovation hub.

More about XFEL: http://www.xfel.eu
More on Hamburg: http://www.hamburg.com

Hamburg Marketing
Guido Neumann
+49-40-300-583    
guido.neumann@marketing.hamburg.de

European XFEL GmbH
Dr Bernd Ebeling
+49-40-8998-6921
press@xfel.eu

PRNews

PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for Its Proprietary DETOUR System for Percutaneous Bypass

Novel technology enables a new, minimally invasive treatment for patients suffering from extremely long peripheral artery blockages

LONDON, Aug. 31, 2017 /PRNewswire/ — Frost & Sullivan is pleased to recognize PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award. PQ Bypass’ DETOUR System is a minimally invasive technology that enables physicians to re-direct, or detour, blood flow around extremely long blockages in the upper leg arteries to restore blood flow to the lower leg and foot.

“PAD is a potentially fatal condition that affects more than 200 million people worldwide—3 to 12% of the global population. PQ Bypass’ proprietary DETOUR System is a promising, innovative approach for patients with extremely long lesions whose current treatment options are not ideal,” said Frost & Sullivan Best Practices Analyst, Norma Vela. “We anticipate rapid, widespread technology adoption once the DETOUR System launches commercially. The global market potential for treating this type of advanced peripheral arterial disease is significant, and PQ Bypass has first-mover status in the space.”

Extremely long blockages in the leg arteries, especially those that are greater than 20 centimeters, are challenging to treat. Historically, physicians have treated these blockages with open bypass surgery (fem-pop bypass), which has the benefit of durability, however, it is associated with an increased risk of complications, longer hospital stays, and prolonged rehabilitation. More recently, minimally-invasive technologies have emerged that go through blockages. These technologies work very well on shorter blockages; however, they have not been as effective on these longer blockages as open surgery.

The DETOUR System is designed to deliver the durability advantages of open bypass surgery with a minimally-invasive approach. During a DETOUR procedure, a pathway is created by crossing from the SFA into the femoral vein and back into the artery that allows DETOUR stent grafts to be placed in a continuous line. The new path through the stent grafts re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient.

“With an increased focus on value-based and patient-centered medicine, surgical advancements that minimize trauma to patients, reduce length of hospital stay and recovery times are critical global needs,” said Richard Ferrari, Chairman of the Board of PQ Bypass. “We designed the DETOUR System to be a transformative step forward in how physicians treat extremely long peripheral artery disease.”

In March 2017, PQ Bypass received CE Mark approval for the DETOUR System and is planning a pivotal investigational device exemption study to support premarket approval from the US Food and Drug Administration (FDA). The clinical results of the DETOUR I trial conducted in Europe were promising, demonstrating excellent safety and effectiveness with patency results of 84.7% at 6 months.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and develops newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices Awards acknowledge companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, and Stryker and also have extensive experience developing medical devices for startups such as Evalve, Access Closure, Avinger, and DVI.

The underlying technology and technique used in the percutaneous PQ DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in PAD.

The PQ Bypass technology platform is not available for sale in the US. For more information, please visit www.pqbypass.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Fit Tech & Gadgets, PRNews

A Glimpse into the Future of Wearable Healthcare: Going Way Beyond Smartwatches and Fitness Trackers

OYSTER BAY, New York, Aug. 30, 2017 /PRNewswire/ — The healthcare wearables market accounts for US$6.8 billion of the current US$25 billion wearables market. ABI Research forecasts that Wearable Healthcare, including healthcare devices, sports, fitness, and wellness trackers will continue to dominate the wearables market and will exceed revenues of US$10 billion in 2022.

Healthcare wearables that monitor health conditions, physical performance, and brain activity will move beyond smartwatches and fitness trackers; they will shrink in size and change in form factor type. Unlike today’s bulky health related devices, ultra-thin and ultra-soft sensors with software analytics make next-generation wearables smarter and more useful. 

“As an ultimate form factor of wearables, flexible body-worn sensors are quite an innovation for wearable adoption in healthcare, fitness, and human-machine interface,” says Marina Lu, Senior Analyst at ABI Research. “These sensors can be integrated into a small patch and attached to human skin surface to track vital signs and other biometrics continuously and wirelessly. Some of the implementation examples include electronic tattoos and skin sweat sensors.”

The electronic tattoo developed by Rotex performs many of the typical functions of smart watches and fitness trackers. Not only does it monitor health conditions in real-time, it also provides a different means to control devices as an integral part of IoT. The low cost and disposability of the electronic tattoos further the use cases and value appeal of wearable technology, especially for customers who are price sensitive.

Replacing costly doctor visits and painful lab-based blood tests, non-invasive sweat sensors can measure a set of key biometrics from a single bead of sweat. A few companies are working to capture the sweat sensor market, such as Eccrine System, GraphWear Technologies and Kenzen.

These sensors require flexible components and startup Royole is leading the way. Royole’s plan for mass production of flexible displays and sensors will accelerate the technology adoption for wearables and facilitate more aesthetically-pleasing wearable designs, smaller form factors, and more immersive experiences.

“Health sensors are becoming increasingly commoditized, as they allow continuously physical monitoring with reduced manual intervention and at low cost,” concludes Lu. “While the miniaturized health sensors enable consumers to monitor health conditions by themselves and be aware of their own health care, they also extend to the enterprise market by delivering superior analytics for clinical and medical research. Once privacy and security concerns are addressed and standardization in health communication protocols are put into place, the next-gen of wearable healthcare will be ushered in.” 

These findings are from ABI Research’s Hot Tech Innovators: Wearables report. This report is part of the company’s Wearables, Usables & Expendables research service, which includes research, data, and analyst insights. 

About ABI Research

ABI Research stands at the forefront of technology market intelligence, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: 

Americas                                      

EMEA/APAC

Deborah Petrara                           

Denise Duffy

Tel: +1.516.624.2558                    

Tel: +44.203.326.0142

pr@abiresearch.com                      

duffy@abiresearch.com
PRNews

Merck Opens its First Customer Food Safety Studio

– New Food Safety Studio in Bellevue, Washington, serves as global center for innovation and collaboration

– Demonstration and training lab space extends product and process development to customers

DARMSTADT, Germany, Aug. 30, 2017 /PRNewswire/ — Merck, a leading science and technology company, has opened its first global Food Safety Studio in Bellevue, Washington for manufacturers of all types of food (beef, poultry, produce, etc.) to collaborate with Merck scientists on developing safety products for rapid detection of foodborne pathogens.

The new 5,300-square foot center gives customers access to a complete food safety workflow, from raw materials testing to finished-product safety testing, to help find, correct and prevent hazards within the food supply chain. The center allows customers to work with many manual or automated food safety products such as testing kits and hygiene swabs that are critical to maintaining safety throughout the manufacturing process.

“The opening of Merck’s Food Safety Studio demonstrates our commitment to ensuring the safety of the global food supply,” said Jean-Charles Wirth, Head of the Applied Solutions business unit, Life Science at Merck. “We are bringing teams together in a workspace designed to foster open innovation and collaboration with the goal of becoming the leader in food safety testing.”

According to the World Health Organization, an estimated 600 million people in the world — almost one-in-10 — fall ill after eating contaminated food, and 420,000 die every year.

Merck, which earlier this year acquired BioControl Systems, a global leader in food safety testing, helps customers protect the global food supply by providing a comprehensive portfolio of state-of-the-art testing technologies.

Customer visits are being scheduled for the new Food Safety Studio, which features a Food Safety Demonstration Center designed with a classroom setting and demonstration lab.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy

– Project is first for Merck’s Massachusetts BioReliance® End-to-End Solutions center

– Collaboration gives Angiex access to Merck’s process development tools and technologies

DARMSTADT, Germany, Aug. 29, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up’s ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

The collaboration with Angiex is the first project to be undertaken at Merck’s new biodevelopment center in Massachusetts, USA. Merck will give Angiex access to end-to-end process development tools, education programs and training to support its success.

“Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer for companies like Angiex.”

Angiex CEO Dr. Paul Jaminet applauded Merck’s broad range of process development capabilities and services for customers at all stages of molecule development and commercialization. “Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate Merck’s expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors,” Jaminet said.

Merck’s BioReliance® End-to-End Solutions deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance® End-to-End Solutions, Merck will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.

Merck’s BioReliance® End-to-End Solutions is part of the Process Solutions business area within the Life Science business of Merck.

About Angiex
Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex is resident at LabCentral in Cambridge, Massachusetts.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Ganeden Brings Probiotic Exhibit and Expertise to Fi Asia

Global leader will discuss probiotic formulation trends, science updates and product launches

CLEVELAND, Aug. 29, 2017 /PRNewswire/ — As probiotic fortification continues to gain momentum around the world, probiotic leader Ganeden is expanding its presence at additional food and beverage events globally—including in Asia. This September, experts from the top probiotic ingredient supplier will be attending Food Ingredients Asia (Fi Asia) in Bangkok. Team members based locally and from the U.S. headquarters will be on site to discuss new probiotic research, offer insight into upcoming product launches and help manufacturers explore innovative probiotic formulations beyond traditional dairy applications.

Ganeden has become a driving force in the probiotic space internationally, helping hundreds of manufacturers use probiotic technology in their products in innovative ways—including many in Asia. As a global leader, the science-driven company is knowledgeable on probiotic trends around the world, including consumer demand, research advancements and innovative options for probiotic fortification beyond the dairy case. Experts can assist in probiotic ingredient selection, including providing details on strain specificity, study requirements and health benefits.

“There are tremendous growth opportunities for probiotic technologies in the Asian market, and Fi Asia gives us a chance to provide expertise on how health benefits can be added to products to drive consumer interest and purchases,” said Stephen Quinn, business and regulatory director for Asia at Ganeden. “We plan to meet with industry leaders and innovators to demonstrate how functional ingredients can benefit end-users and grow business. There is a strong tradition of probiotics in Asia, but nearly all of it is in the supplement and dairy categories, so having a chance to provide the same health benefits in other food and beverage applications is exciting for manufacturers and their customers.”

Ganeden is best known for GanedenBC30® (Bacillus coagulans GBI-30, 6086), its patented and shelf stable probiotic ingredient that remains viable through most manufacturing processes, shelf life and gastric transit—allowing it to be fortified into almost any food or beverage product. Years of ongoing studies confirm the strain’s safety, digestive and immune support, and protein utilization benefits. And because GanedenBC30 has been shown to survive 10X more effectively than yogurt cultures, it has become one of the top ingredient choices for probiotic benefits in both refrigerated and non-refrigerated products.

During the show, Ganeden will also introduce the newest addition to its ingredient portfolio—Staimune™. The new ingredient uses the inactivated cells of GanedenBC30, which have been shown to support immune health. Staimune’s ease of formulation opens up new opportunities in immune-focused, functional foods and beverages which involve processes too harsh for live probiotics.

To meet with probiotic experts at the Fi Asia show, contact Ganeden or visit booth #F34. For more information on the probiotic company, including its ingredient portfolio, research and international presence, visit GandedenProbiotics.com.

About Ganeden:

Ganeden® is at the forefront of probiotic research and product development with an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30®, its patented, FDA GRAS, highly stable probiotic ingredient. Through the fermentation process of GanedenBC30, Ganeden developed Bonicel®, the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden’s newest ingredient, Staimune™ is a patented probiotic technology comprising of inactivated GanedenBC30 which has been shown to have immune benefits. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com. 

PRNews

Merck to Acquire Natrix Separations to Advance Next-Generation Processing Capabilities

— Boosts Merck’s single-use chromatography portfolio

— Accelerates Merck’s mAb and vaccine manufacturing offering

DARMSTADT, Germany, Aug. 28, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced that it has entered into an agreement to acquire Natrix Separations, an Ontario, Canada-based provider of hydrogel membrane products for single-use chromatography. The transaction is expected to close in Q3 of 2017. Financial details were not disclosed.


Merck signed an agreement to acquire Natrix Separations, a company known for its technology platform capable of delivering high productivity and impurity removal in a single-use format. This acquisition complements Merck’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for customers. Pictured here is a magnified view of the Natrix HD Membrane pore structure, comprised of up to 95 percent functional monomer.

Natrix is known for its unique technology platform capable of delivering high productivity and impurity removal in a single-use format, an ideal fit with next-generation processing. This acquisition complements Merck’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for its customers.

“The Natrix technology platform, and the development options and capabilities that this brings for single-use and rapid cycling chromatography, will allow us to accelerate our offering in mAb and vaccine manufacturing,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “This acquisition creates tremendous opportunity to drive growth and advancement in next-generation processing—an area of increasing importance to our customers.”

Next-generation processing is any technology, expendable or system that changes the existing monoclonal antibody manufacturing template through unit operation intensification, connection of unit operations, or fully continuous processing. Biomanufacturers are moving toward next-generation processing because of its many benefits, including increased plant productivity, facility flexibility, cost efficiencies and reduced risk. Next-generation processing is expected to triple in market size between 2020 and 2025.

Natrix markets both an anion exchange membrane and cation exchange membrane. Natrix is developing additional products to enable a fully single-use, full-scale biological purification process.

“Joining Merck gives us the opportunity to collaborate with some of the best minds in the industry, allowing us to further the great work done by our scientists,” says John Chickosky, CEO, Natrix Separations. “I am truly excited to become part of a larger effort and see the benefits of this combination in the advances we will make for our customers and the global scientific community.”

About Natrix Separations, Inc.
 Natrix Separations enables fast and flexible manufacturing of biopharmaceuticals through high-productivity disposable downstream processing products. The innovative Natrix HD Membranes overcome the limitations in efficiency, speed, and flexibility imposed by conventional capital-intensive approaches to chromatography. Natrix products feature well-established industry-standard chemistries, and are scalable from R&D to commercial manufacturing. Natrix is headquartered in Burlington, Ontario, Canada. For additional information, visit www.natrixseparations.com

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
 Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo – https://mma.prnewswire.com/media/548923/Merck_Acquires_Natrix_Separations.jpg

Exit mobile version